Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02216617 | Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy(TAPIS) | completed | Phase 1 | 8 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01721525 | Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02262741 | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | completed | Phase 1 | 71 | MedImmune LLCINDUSTRY | 2 | Oct 23, 2017 | clinicaltrials |
| NCT02906800 | Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients(DIGHANC) | unknown | Phase 1 / Phase 2 | 15 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT03282617 | Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 | 55 | National University Hospital, SingaporeOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | withdrawn | Phase 1 | 0 | Robert FerrisOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02456701 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | completed | Phase 1 | 7 | Celldex TherapeuticsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | terminated | Phase 1 | 5 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01733823 | DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole | completed | Phase 1 / Phase 2 | 31 | Danish Head and Neck Cancer GroupNETWORK | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00704639 | Chemoradiation Treatment for Head and Neck Cancer | completed | Phase 1 / Phase 2 | 60 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT00471471 | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 22 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00626639 | A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy | completed | Phase 1 / Phase 2 | 5 | Swedish Orphan BiovitrumINDUSTRY | 0 | Jun 21, 2017 | clinicaltrials |
| NCT00006107 | Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 1 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02251639 | Diagnostic Aids for Detection and Diagnosis of Oral Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 27, 2017 | clinicaltrials |
| NCT00937417 | S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT00004070 | Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer | completed | Phase 1 / Phase 2 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT02110082 | Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | completed | Phase 1 | 66 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00431210 | Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00970502 | Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | completed | Phase 1 / Phase 2 | 15 | Johnny KaoOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00513383 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00903461 | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 | 7 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)(NATELLA) | completed | Phase 1 | 23 | Baylor College of MedicineOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00927147 | Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 17 | Boneca CorporationINDUSTRY | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01604759 | Polarized Reflectance Spectroscopy for Oral Lesions(PolProbe) | completed | Phase 1 | 40 | British Columbia Cancer AgencyOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT00003200 | Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | terminated | Phase 1 / Phase 2 | 3 | Innate PharmaINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT00705640 | Vaccine Therapy in Treating Patients With Advanced Melanoma(Mel48) | completed | Phase 1 | 45 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT00003582 | Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer | completed | Phase 1 / Phase 2 | 36 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01283178 | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC | terminated | Phase 1 | 3 | Virginia Commonwealth UniversityOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01921426 | A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | completed | Phase 1 | 30 | Galera Therapeutics, Inc.INDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01046266 | A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 62 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2016 | clinicaltrials |
| NCT00450138 | Open Label, Phase I ZD6474 Head and Neck Cancer Study | completed | Phase 1 | 48 | SanofiINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT01975688 | A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | terminated | Phase 1 | 10 | GW Pharmaceuticals LtdINDUSTRY | 1 | Aug 11, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 29, 2017source: clinicaltrials